Iris Bigalke

659 total citations
26 papers, 494 citations indexed

About

Iris Bigalke is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Iris Bigalke has authored 26 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 17 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Iris Bigalke's work include Immunotherapy and Immune Responses (20 papers), RNA Interference and Gene Delivery (12 papers) and CAR-T cell therapy research (11 papers). Iris Bigalke is often cited by papers focused on Immunotherapy and Immune Responses (20 papers), RNA Interference and Gene Delivery (12 papers) and CAR-T cell therapy research (11 papers). Iris Bigalke collaborates with scholars based in Norway, Germany and United States. Iris Bigalke's co-authors include Dolores J. Schendel, Bernhard Frankenberger, Stefanie Tippmer, Heike Pohla, Elisabeth Kremmer, Anke Zobywalski, Johanna Tischer, Hans‐Jochem Kolb, Georg Ledderose and Andreas Moosmann and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Iris Bigalke

25 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iris Bigalke Norway 8 315 262 112 111 63 26 494
Jason L. Yovandich United States 11 696 2.2× 464 1.8× 88 0.8× 112 1.0× 82 1.3× 12 873
Simone Kayser Germany 10 264 0.8× 394 1.5× 180 1.6× 71 0.6× 130 2.1× 16 578
Monika Laumer Germany 8 596 1.9× 414 1.6× 54 0.5× 116 1.0× 94 1.5× 9 714
Victoria Marcu‐Malina Israel 11 322 1.0× 162 0.6× 99 0.9× 188 1.7× 37 0.6× 17 554
György Stuber Sweden 14 468 1.5× 334 1.3× 141 1.3× 149 1.3× 30 0.5× 22 716
Henrike Reinhard Germany 13 259 0.8× 121 0.5× 198 1.8× 118 1.1× 33 0.5× 20 515
Korina G. Veenstra United States 6 317 1.0× 216 0.8× 40 0.4× 139 1.3× 54 0.9× 8 484
Thomas Leemhuis United States 10 204 0.6× 295 1.1× 85 0.8× 195 1.8× 160 2.5× 13 555
Carmen Stecher Austria 5 420 1.3× 222 0.8× 45 0.4× 75 0.7× 42 0.7× 11 532
Kaiping Han United States 9 638 2.0× 472 1.8× 47 0.4× 105 0.9× 34 0.5× 15 795

Countries citing papers authored by Iris Bigalke

Since Specialization
Citations

This map shows the geographic impact of Iris Bigalke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Bigalke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Bigalke more than expected).

Fields of papers citing papers by Iris Bigalke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Bigalke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Bigalke. The network helps show where Iris Bigalke may publish in the future.

Co-authorship network of co-authors of Iris Bigalke

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Bigalke. A scholar is included among the top collaborators of Iris Bigalke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Bigalke. Iris Bigalke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maggadóttir, Sólrún Melkorka, Svein Dueland, Nadia Mensali, et al.. (2024). Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer. Molecular Therapy. 32(6). 2021–2029. 4 indexed citations
2.
Fløisand, Yngvar, Mats Remberger, Iris Bigalke, et al.. (2023). WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. Leukemia. 37(9). 1842–1849. 16 indexed citations
3.
Axcrona, Karol, Ulrika Axcrona, Iris Bigalke, et al.. (2021). Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy. The Prostate. 82(2). 245–253. 22 indexed citations
4.
5.
Raffegerst, Silke, Yngvar Fløisand, Dag Josefsen, et al.. (2019). DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment. Blood. 134(Supplement_1). 3923–3923. 5 indexed citations
6.
7.
Bigalke, Iris, Yngvar Fløisand, Dag Josefsen, et al.. (2018). Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use. Blood. 132(Supplement 1). 2718–2718. 2 indexed citations
8.
Bigalke, Iris, Karol Axcrona, Else Marit Inderberg, et al.. (2017). Results from a first in man Phase I/II adjuvant Dendritic Cell Vaccine study in high risk prostate cancer patients following radical surgery. Cytotherapy. 19(5). S15–S15. 1 indexed citations
9.
Bigalke, Iris, Dag Josefsen, Yngvar Fløisand, et al.. (2017). Abstract 3659: WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival. Cancer Research. 77(13_Supplement). 3659–3659.
10.
Lichtenegger, Felix S., Katrin Deiser, Frauke M. Schnorfeil, et al.. (2016). Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade. Blood. 128(22). 764–764. 8 indexed citations
11.
Bigalke, Iris, et al.. (2015). Abstract 2516: A new generation of dendritic cells to improve cancer therapy shows prolonged progression-free survival in patients with solid tumors. Cancer Research. 75(15_Supplement). 2516–2516. 3 indexed citations
12.
Henschler, Reinhard, et al.. (2015). ITOC2 – 022. Vaccination with next-generation dendritic cells for AML postremission therapy induces antigen-specific T cell responses. European Journal of Cancer. 51. S8–S8. 2 indexed citations
13.
14.
Subklewe, Marion, et al.. (2014). New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunology Immunotherapy. 63(10). 1093–1103. 32 indexed citations
15.
Lichtenegger, Felix S., Thomas Köhnke, Veit Bücklein, et al.. (2014). Next-generation dendritic cells for immunotherapy of acute myeloid leukemia. Journal for ImmunoTherapy of Cancer. 2(S3). 3 indexed citations
16.
Moosmann, Andreas, Iris Bigalke, Johanna Tischer, et al.. (2010). Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 115(14). 2960–2970. 173 indexed citations
17.
Zobywalski, Anke, Bernhard Frankenberger, Heike Pohla, et al.. (2007). Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. Journal of Translational Medicine. 5(1). 18–18. 112 indexed citations
18.
Kolb, Hans‐Jochem, Iris Bigalke, Johanna Tischer, et al.. (2005). Risk Factors of HLA-Haploidentical Transplantation Using the Combination of Unmodified Marrow and CD6-Depleted G-CSF Mobilized Blood Cells.. Blood. 106(11). 2907–2907. 5 indexed citations
19.
Kolb, Hans‐Jochem, Iris Bigalke, Belinda Pinto Simões, et al.. (2004). CD6-Depleted Mobilized Stem Cells for Modification of HVG and GVH Reactions after HLA-Haploidentical Marrow Transplantation.. Blood. 104(11). 978–978. 4 indexed citations
20.
Offner, Felix, Hans G. Feichtinger, Iris Bigalke, et al.. (1993). Interaction of human malignant melanoma tumor spheroids with endothelium and reconstituted basement membrane: Modulation by RGDS. International Journal of Cancer. 54(3). 506–512. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jason L. Yovandich Breakdown of academic impact, for papers by Simone Kayser Breakdown of academic impact, for papers by Monika Laumer Breakdown of academic impact, for papers by Victoria Marcu‐Malina Breakdown of academic impact, for papers by György Stuber Breakdown of academic impact, for papers by Henrike Reinhard Breakdown of academic impact, for papers by Korina G. Veenstra Breakdown of academic impact, for papers by Thomas Leemhuis Breakdown of academic impact, for papers by Carmen Stecher Breakdown of academic impact, for papers by Kaiping Han
Rankless by CCL
2026